NCBI Logo
GEO Logo
   NCBI > GEO > Accession DisplayHelp Not logged in | LoginHelp
GEO help: Mouse over screen elements for information.
          Go
Series GSE153792 Query DataSets for GSE153792
Status Public on Jul 05, 2020
Title Whole-blood transcriptome profiling reveals signatures of metformin and its therapeutic response
Organism Homo sapiens
Experiment type Expression profiling by high throughput sequencing
Summary Metformin, a biguanide agent, is the first-line treatment for type 2 diabetes mellitus due to its glucose-lowering effect. Despite its wide application in the treatment of multiple health conditions, the glycemic response to metformin is highly variable, emphasizing the need for reliable biomarkers. We chose the RNA-Seq-based comparative transcriptomics approach to evaluate the systemic effect of metformin and highlight potential predictive biomarkers of metformin response in drug-naïve type 2 diabetes patient volunteers in vivo. Longitudinal blood-derived transcriptome analysis revealed metformin-induced differential expression of novel and previously described genes involved in cholesterol homeostasis (SLC46A1 and LRP1), cancer development (CYP1B1, STAB1, CCR2, TMEM176B) and immune responses (CD14, CD163) after administration of metformin for three months. We demonstrate for the first time transcriptome-based molecular discrimination between metformin responders (delta HbA1c ≥ 1% or 12.6 mmol/mol) and non-responders (delta HbA1c < 1% or 12.6 mmol/mol) determined by expression levels of 56 genes, explaining 13.9% of the variance in the therapeutic efficacy of the drug. Moreover, we found a significant upregulation of IRS2 gene (log2FC 0.89) in responders compared to non-responders before the use of metformin. Finally, we provide evidence for the mitochondrial respiratory complex I as one of the factors related to the high variability of the therapeutic response to metforminin patients with type 2 diabetes mellitus.
 
Overall design Longitudinal RNA-Seq data of venous blood samples collected from 17 type 2 diabetes mellitus patients in two consecutive time points:before administration of metformin, after 3 months of metformin therapy.
 
Contributor(s) Ustinova M, Ansone L, Silamikelis I, Rovite V, Elbere I, Silamikele L, Kalnina I, Fridmanis D, Sokolovska J, Konrade I, Pirags V, Klovins J
Citation missing Has this study been published? Please login to update or notify GEO.
Submission date Jul 04, 2020
Last update date Jul 05, 2020
Contact name Monta Ustinova
E-mail(s) monta.ustinova@biomed.lu.lv
Organization name Latvian Biomedical Research and Study Centre
Street address Ratsupites 1
City Riga
ZIP/Postal code LV-1067
Country Latvia
 
Platforms (1)
GPL17303 Ion Torrent Proton (Homo sapiens)
Samples (34)
GSM4654147 1_1
GSM4654148 1_2
GSM4654149 2_1
Relations
BioProject PRJNA644109
SRA SRP269998

Download family Format
SOFT formatted family file(s) SOFTHelp
MINiML formatted family file(s) MINiMLHelp
Series Matrix File(s) TXTHelp

Supplementary file Size Download File type/resource
GSE153792_read_counts.txt.gz 1.3 Mb (ftp)(http) TXT
SRA Run SelectorHelp
Raw data are available in SRA
Processed data are available on Series record

| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap